Genmab Announces Progress With DuoBody(TM) Platform

Genmab A/S has announced that the company has entered a research collaboration with an as yet undisclosed, new large pharmaceutical partner to investigate a bispecific antibody-drug conjugate using Genmab's DuoBody technology in combination with a novel antibody-drug conjugate technology platform from the pharma company. If successful, the parties may decide to enter into a license agreement to further develop a new DuoBody-ADC product. The target in the collaboration is clinically validated and expressed on solid tumors.

"This research collaboration with a large pharma company marks a first step in our strategy to sign different types of partnership based on our innovative bispecific antibody technology. This partnership will help us to investigate the use of our DuoBody platform in creating more effective treatments for cancer," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.


For more information, please contact:

Rachel Curtis Gravesen,
Senior Vice President,
Tel: +45 33 44 77 20
E-mail: r.gravesen@genmab.com